Korean J Hematol.  1999 Aug;34(3):507-511.

A Case of Non-Immune Mediated Marrow Suppression Associated with Phenytoin Therapy

Affiliations
  • 1Department of Hematology-Oncology, College of Medicine, Ajou University, Suwon, Korea.

Abstract

Diphenylhydantoin (DPH) is one of the most widely used anticonvulsants for treatment and prevention of seizures. However it is frequently associated with drug-induced leukopenia. Hypersensitivity reactions to phenytoin are well recognized and can be severe. Phenytoin is associated with serious hematologic side effects such as agranulocytosis, thrombocytopenia, red cell aplasia and hemolytic anemia, either through humoral or cell-mediated immunemechanism. We describe a 57-year-old male patient who developed a severe granulocytopenia while taking phenytoin for 66 days in the total amount of 21.6 gram. Bone marrow examination showed isolated depletion of myeloid elements. After 10 days of phenytoin withdrawal and G-CSF treatment, the patient recovered from granulocytic suppression. Using in vitro culture, marrow suppression associated with phenytoin therapy was felt to be non-immune mediated marrow suppression.

Keyword

Phenytoin; Leukopenia; Agranulocytosis

MeSH Terms

Agranulocytosis
Anemia, Hemolytic
Anticonvulsants
Bone Marrow Examination
Bone Marrow*
Granulocyte Colony-Stimulating Factor
Humans
Hypersensitivity
Leukopenia
Male
Middle Aged
Phenytoin*
Seizures
Thrombocytopenia
Anticonvulsants
Granulocyte Colony-Stimulating Factor
Phenytoin
Full Text Links
  • KJH
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr